FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer.

Curr Med Chem

Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, University of Exeter, Hatherly Laboratories, Streatham Campus, Exeter, EX4 4PS, UK.

Published: January 2025

Download full-text PDF

Source
http://dx.doi.org/10.2174/0109298673365863250101070254DOI Listing

Publication Analysis

Top Keywords

fda approves
4
approves inavolisib
4
inavolisib combo
4
combo pik3ca-mutated
4
pik3ca-mutated hr+
4
hr+ breast
4
breast cancer
4
fda
1
inavolisib
1
combo
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!